BIOLARGO, INC. - What You Need to Know

Thinking about investing in BioLargo? It is an interesting company, but look under the hood before you invest. Here is the plain-English breakdown.

1. What does this company actually do?

BioLargo develops and sells environmental technologies. They identify, patent, and commercialize new ideas. Their core business includes:

• Water Treatment: Their AEC system removes "forever chemicals" (PFAS) from water.
• Odor and VOC Control: Their main product, CupriDyne Clean, neutralizes odors in waste and livestock facilities.
• Air Quality: They develop advanced air filtration systems.
• Engineering Services: Their subsidiary, BLEST, provides contract engineering for other companies. This brings in cash while they develop their own products.
• Emerging Tech: They are researching medical uses for antimicrobial tech and early-stage liquid sodium batteries.

2. How do they make money and are they growing?

BioLargo earns money through product sales, engineering fees, and licensing agreements.

The reality check: They are not yet profitable. They have lost money since they started. As of March 31, 2025, they reported a total loss of about $150.7 million over their lifetime. Their finances are fragile. One single customer provided 77% of their revenue in early 2025. If they lose that contract, the company may struggle to keep operating.

3. What is this "Offering" about?

This is a "resale" filing. Existing shareholders are registering their shares so they can sell them on the open market. BioLargo is not issuing new shares here, so the company gets no money from these specific sales. However, if holders of existing warrants choose to use them, BioLargo could receive up to $7.95 million. The company would use that money for research, marketing, and daily operations.

4. What are the main risks?

• "Going Concern" Warning: Auditors have warned that there is real doubt about whether BioLargo can stay in business unless they turn a profit or raise more cash.
• "Penny Stock" Status: The stock trades on the OTCQX market, not a major exchange like the NYSE. This means fewer people trade it, prices can swing wildly, and it is harder to buy or sell quickly.
• Dilution: The company often pays employees and consultants with stock instead of cash. They also sell new shares to raise money. This creates more shares, which reduces your ownership percentage and the value of your stake.
• Volatility: The stock is highly speculative. As of June 10, 2025, it traded at $0.205 per share. The price changes rapidly based on the company’s ability to hit goals or manage its cash.
• No Dividends: The company has never paid a dividend and plans to keep all earnings to grow the business. Do not expect income from this stock.

5. Who’s running the show?

CEO Dennis Calvert leads the company. BioLargo notes that the business relies heavily on his leadership and industry ties. Losing him could hurt the company’s ability to execute its strategy or secure partnerships.

Final Takeaway

BioLargo is a high-risk, speculative investment. They are currently in a race to reach profitability before their cash reserves run out. Because of the "going concern" warning and the heavy reliance on a single customer, this is not a "set it and forget it" investment. Only consider putting money here if you are comfortable with the possibility of losing your entire investment.

Disclaimer: I am an AI, not a financial advisor. This guide is for informational purposes only. Always do your own research and consult with a qualified professional before making investment decisions.